摘要
目的总结并分析以往齐拉西酮在治疗首发精神分裂症的临床经验,为日后的精神分裂症的临床治疗提供指导性建议。方法选取在我院接受治疗的40例首发性精神分类症患者,将其分为观察组与对照组,对两组患者进行为期3个月的治疗。采用IPROS对患者精神状况进行评估,采用PSP对患者社会功能进行评估。结果经治疗后,两组IPROS与PSP均有所变化,观察组评分变化幅度大于对照组。结论齐拉西酮是治疗首发精神分裂的有效药物。
Objective To summarize and analyze the clinical experience of ziprasidone in the treatment of first-episode schizophrenia,for future spirit schizophrenia clinical treatment to provide guidance and advice. Methods 40 patients with first episode of psychosis in our hospital were divided into observation group and control group,two groups of patients were treated for 3 months. IPROS was used to evaluate the mental status of the patients,and the social function of the patients was evaluated by PSP. Results After treatment,the two groups of IPROS and PSP were changed,the observation group was significantly higher than the control group. Conclusion Ziprasidone is an effective drug for the treatment of schizophrenia.
出处
《中国卫生标准管理》
2016年第12期89-90,共2页
China Health Standard Management
